. 2014 Mar 20;8(2):198–215. doi: 10.1007/s12072-014-9523-y

Table 2.

Main characteristics of clinical interventions in Tac-based immunosuppressive regimens during liver transplantation

First author	Year	Study center	Group	No of patients (n)	Etiology distribution (n)						Intraoperative steroid usage	Postoperative steroid duration	Tac duration	MMF duration	Tac blood level (ng/mL)
First author	Year	Study center	Group	No of patients (n)	HBV	HCV	HCC	PSC/PBC	Alcohol	AIH	Intraoperative steroid usage	Postoperative steroid duration	Tac duration	MMF duration	7 day	28 day	90 day
Comparison of Tac-based regimen with steroid or not (Sect. I)
Langrehr [25]	2002	University of Berlin, Germany	Tac + steroid	15		15					+	14 m
Langrehr [25]	2002	University of Berlin, Germany	Tac + MMF	15		15					+	One bolus
Pelletier [26]	2005	University of Michigan, Ann Arbor, USA	Tac + MMF + steroid	36		24	8		13		+	6 m	14.0 m	14 m
Pelletier [26]	2005	University of Michigan, Ann Arbor, USA	Tac + MMF	36		14	6		17				14.0 m	14 m
Margarit [27]	2005	Universidad Autònoma Barcelona, Spain	Tac + steroid	32	2	15	11		11		+	3 m	44.0 m		12.0	13.0	10.0
Margarit [27]	2005	Universidad Autònoma Barcelona, Spain	Tac	28	3	20	13		5		+		44.0 m		12.5	14.0	10.5
Reggiani [17]	2005	Instituto di Ricovero e Cura a Caraterre Scientifico (IRCCS) Policlinico San Matteo, Italy	Tac + MMF + steroid	18			12	1	1		+	3 m	31.0 m	31 m	11.0	12.0
Reggiani [17]	2005		Tac + MMF	12			2	0	2				31.0 m	31 m	14.8	11.0
Junge [28]	2005	Charité Berlin Campus Virchow Klinikum, Germany	Tac + steroid	14						14		3 m	24.0 m	24 m
Junge [28]	2005	Charité Berlin Campus Virchow Klinikum, Germany	Tac + MMF	16						16			24.0 m	24 m
Chen [9]	2007	Tongji Medical College, China	Tac + MMF + steroid	26			26				+	12 m	12.0 m	12 m
Chen [9]	2007	Tongji Medical College, China	Tac + MMF	28			28				+	3 m	12.0 m	12 m
Vivarelli [29]	2007	University of Bologna, Italy	Tac + steroid	16							+	24 m	28.0 m		11.2	11.5	8.0
Vivarelli [29]	2007	University of Bologna, Italy	Tac	23							+	3 m	28.0 m		12.0	11.1	9.1
Manousou [30]	2009	University College London, UK	Azathioprine + steroid + Tac	49		49	13					6 m	53.5 m			8.4	7.0
Manousou [30]	2009	University College London, UK	Tac	54		54	17						53.5 m			8.0	8.0
Weiler [31]	2010	Hospital of Johannes Gutenberg University Mainz, Germany	Tac + steroid	54	7	16	19	5	21		+	6 m	60.0 m
Weiler [31]	2010	Hospital of Johannes Gutenberg University Mainz, Germany	Tac	56	12	14	21	3	16		+	2w	60.0 m
Comparison of Tac-based regimen with induction agents or not (Sect. II)
Eason [32]	2003	Ochsner Clinic Foundation, USA	Tac + MMF + steroid	59	1	34		6		3	+	3 m	18.0 m	3 m
Eason [32]	2003	Ochsner Clinic Foundation, USA	RATG + Tac + MMF	60	3	31		3		3			18.0 m	3 m
Boillot [33]	2005	Hospital Edouard Herriot, France	Tac + steroid	347	55	103	50				+	3 m	3.0 m				10.9
Boillot [33]	2005	Hospital Edouard Herriot, France	Daclizumab + Tac	351	63	106	53				+		3.0 m				10.6
Spada [34]	2006	University of Pittsburgh Medical Center, Italy	Tac + steroid	36							+	6 m	24.0 m		7.8		9.3
Spada [34]	2006	University of Pittsburgh Medical Center, Italy	Basiliximab + Tac	36							+		24.0 m		9.9		7.5
Humar [35]	2007	University of Minnesota Minneapolis, USA	Tac + MMF + steroid	83		42					+	6 m	32.0 m	3 m
Humar [35]	2007	University of Minnesota Minneapolis, USA	Basiliximab + Tac + MMF	83		44					+	6d	16.1 m	3 m
Kato [36]	2007	University of Miami School of Medicine, USA	Tac/MMF + steroid	39		39					+	3 m	52.0 m	12 m
Kato [36]	2007	University of Miami School of Medicine, USA	Daclizumab + Tac/MMF	31		31							52.0 m	12 m
Gras [37]	2008	Luc University Clinics, Université Catholique de Louvain, Belgium	Tac + steroid	34			4				+	60 m	60.0 m		11.8	8.8	7.7
Gras [37]	2008		Basiliximab + Tac	50			8						60.0 m		9.9	9.0	6.9
Foroncewicz [18]	2009	Medical University of Warsaw, Poland	Tac + steroid	18	2	2		5	2		+	72 m	72.0 m
Foroncewicz [18]	2009	Medical University of Warsaw, Poland	Daclizumab + Tac	7	0	3		2	1		+		72.0 m
Klintmalm [38]	2011	Baylor University Medical Center, USA	Tac + MMF + steroid	72		72					+	20.9 m	20.9 m	20.9 m	11.1	11.1	11.1
Klintmalm [38]	2011	Baylor University Medical Center, USA	Daclizumab + Tac + MMF	146		146							20.9 m	20.9 m	10.8	11.1	9.6

AIH autoimmune hepatitis, HBV hepatitis B virus, HCV hepatitis C virus, HCC hepatocellular carcinoma, MMF mycophenolate mofetil, PBC primary biliary cirrhosis, PSC primary sclerosing cholangitis, RATG rabbit antithymocyte globulin, Tac tacrolimus